Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Guidelines

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Conferences

Conference Coverage

Conference Listing

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Formulary Central

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Sabrina McCrear is an assistant editor for 

 (AJMC®), which she joined in 2025. She produces written and video content across a range of disease areas and manages social media platforms for 

Sabrina holds a B.A. in Journalism with a minor in Biology from Howard University in Washington, D.C. You can connect with her on 

Sachin H. Jain, MD, MBA, discusses 2026 health care predictions, including AI adoption, GLP-1 demand, MAHA growth, DEI’s return, and policy shifts.

2026 Health Care Predictions: AI, GLP-1s, MAHA, DEI: Sachin H. Jain, MD, MBA

Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.

She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on 

Articles

ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell carcinoma, and health equity.

ICYMI: Highlights From ASCO GU 2025

Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (

®). She joined AJMC® in 2013 and is the primary staff editor for 

the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for 

®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for 

Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on 

Reader favorites from the 2025 Patient-Centered Oncology Care conference included articles and interviews featuring AI's role in precision medicine and the importance of collaboration in delivering care.

ICYMI: Highlights From Patient-Centered Oncology Care®

DeFi trial results show that continuous nirogacestat provides durable tumor control, ongoing shrinkage, sustained symptom improvement, and a stable safety profile over several years.

Long-Term Trial Shows Durable Efficacy, QOL Gains With Nirogacestat in Desmoid Tumors

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Combination therapy in lymphoma continued to make news in 2025, whether built around bispecific antibodies, notably epcoritamab (Epkinly), or antibody drug conjugates, such as polatuzumab vedotin (Polivy). Data from EPCORE NHL-2 in diffuse large B-cell lymphoma (DLBCL) made news at the European Hematology Association 2025 Congress, showing that epcoritamab plus chemoimmunotherapy brought an 87% response rate in R/R DLBCL. The big news came November 18, when the FDA approved the epcoritamab plus R

 regimen (rituxan plus lenalidomide) in second-line follicular lymphoma. Full data for the EPCORE FL-1 trial will be presented at the American Society of Hematology in December 2025.

Combination therapies in lymphoma, particularly those involving bispecific antibodies like epcoritamab and antibody-drug conjugates such as polatuzumab vedotin, have shown significant progress in 2025. Notably, the EPCORE NHL-2 trial demonstrated an 87% response rate in relapsed/refractory diffuse large B-cell lymphoma with epcoritamab plus chemoimmunotherapy. A major development occurred with the FDA's approval of the epcoritamab plus R2 regimen for second-line follicular lymphoma. Anticipation builds for the full EPCORE FL-1 trial data presentation at the upcoming American Society of Hematology meeting.

2025 Year in Review: Lymphoma

Supplements and Featured Publications